All In Biotech

Drug Trial Radar · NCT01122030

Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

Last checked: Nov 20, 2026Latest source record: May 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

72

Actual

Start

May 19, 2010

Primary completion

Feb 23, 2011

Study completion Mar 22, 2011

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
May 12, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the safety of single doses of oral naldemedine in adults physically dependent on opioids.

Conditions

  • Opioid Induced Bowel Dysfunction

Interventions

  • NaldemedineDrug

    Tablets or solution for oral administration

  • PlaceboDrug

    Tablets or solution for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: From the first dose of study drug on Day 15 up to Day 24.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shionogi Research Site

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.